MedTrace Logo

Abbott Medical - VERITAS Study

NCT06707688 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 458

Last updated 2026-02-18

No results posted yet for this study

Summary

The primary objective of this study is to evaluate the safety and effectiveness of Abbott's Amulet™ 2 Left Atrial Appendage (LAA) occluder device (Amulet 2 device) in patients who have non-valvular atrial fibrillation and who are at increased risk for stroke and systemic embolism and have appropriate rationale to seek a non-pharmacologic alternative to oral anticoagulation.

Conditions

  • Atrial Fibrillation (AF)
  • Stoke

Interventions

DEVICE

Amulet™ 2 Left Atrial Appendage (LAA) Occluder

Patient will undergo the implantation of the Amulet™ 2 Left Atrial Appendage (LAA) Occluder

Sponsors & Collaborators

  • Abbott Medical Devices

    lead INDUSTRY

Principal Investigators

  • Ryan Palmer · Abbott Medical

  • Devi Nair, MD · Arrhythmia Research Group

  • Mohamad Alkhouli, MD · Mayo Clinic

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-07
Primary Completion
2025-11-06
Completion
2027-09-30
FDA Device
Yes

Countries

  • United States
  • Belgium
  • Canada
  • Denmark
  • France
  • Germany
  • Italy
  • Spain
  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06707688 on ClinicalTrials.gov